1512

É UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vered HORNIK et al.

Confirmation No.: 3691

Application No.: 09/734,583

Group Art Unit: 1654

Filing Date:

December 13, 2000

Examiner: Maury A. Audet

For: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN Attorney Docket No.: 87534-3000

ANALOGS

REQUEST FOR CORRECTION OF FILING RECEIPT

Office of Initial Patent Examination **Customer Service Center** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

6/16/04

Sir:

A Filing Receipt for the above-identified application has been received and the following correction is respectfully requested.

At "Domestic Priority data as claimed by applicant", please change:

"THIS APPLICATION IS A CIP OF PCT/IL99/00329 06/15/1999" to

--THIS APPLICATION IS A CON OF PCT/IL99/00239 06/15/1999--

Support for this correction can be found in the first sentence of page 1 of the specification as filed on December 13, 2000, a copy of which is attached hereto. Also enclosed is a copy of the Filing Receipt with the requested change noted thereon.

No fee is believed to be due for this submission. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814.


Respectfully submitted,

Date

Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP Customer No. 28765

202-371-5904



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

vop.otgau.www

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** TOT CLAIMS IND CLAIMS 09/734.583 12/13/2000 1614 391 2254-030 24

87534-3**000**

CONFIRMATION NO. 3691

FILING RECEIPT

'OC000000006244971'

20582 PENNIE & EDMONDS LLP 1667 K STREET NW **SUITE 1000** WASHINGTON, DC 20006

Date Mailed: 06/29/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBÉR, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Vered Hornik, Rehovot, ISRAEL; Michel M. Afargan, Raanana, ISRAEL; Gary Gellerman, Rishon LeZion, ISRAEL;

Domestic Priority data as claimed by applicant _CON

THIS APPLICATION IS A GIP OF PCT/IL99/00329 06/15/1999 WHICH IS A CIP OF 09/203,389 12/02/1998 WHICH IS A CIP OF 09/100,360 06/19/1998 PAT 6,051,554

Foreign Applications

If Required, Foreign Filing License Granted 06/29/2001

Projected Publication Date: 10/11/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN ANALOGS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of the United States national stage designation of PCT application no. PCT/IL99/00329 filed June 15, 1999, which is a continuation-in-part of application no. 09/203,389 filed December 2, 1998 which in turn is a continuation-in-part of application no. 09/100,360 filed June 19, 1998, now U.S. patent 6,051,554.

10 FIELD OF THE INVENTION

The present invention relates to conformationally constrained N^{α} backbone-cyclized somatostatin analogs cyclized via novel linkages, and to pharmaceutical compositions containing same.

15 BACKGROUND OF THE INVENTION

Somatostatin analogs

Somatostatin is a cyclic tetradecapeptide found both in the central nervous system and in peripheral tissues. It was originally isolated from mammalian hypothalamus and identified as an important inhibitor of growth hormone secretion from the anterior pituitary. Its multiple biological activities include inhibition of the secretion of glucagon and insulin from the pancreas, regulation of most gut hormones and regulation of the release of other neurotransmitters involved in motor activity and cognitive processes throughout the central nervous system (for review see Lamberts, *Endocrine Rev.*, 9:427, 1988). Additionally, somatostatin and its analogs are potentially useful antiproliferative agents for the treatment of various types of tumors.

Natural somatostatin (also known as Somatotropin Release Inhibiting Factor, SRIF) of the following structure:

 $30 \quad H-Ala^{1}-Gly^{2}-Cys^{3}-Lys^{4}-Asn^{5}-Phe^{6}-Phe^{7}-Trp^{8}-Lys^{9}-Thr^{10}-Phe^{11}-Thr^{12}-Ser^{13}-Cys^{14}-OH$

was first isolated by Guillemin and colleagues (Bruzeau et al. Science, 179:78, 1973). It exerts its effect by interacting with a family of receptors. Recently, five receptor subtypes, termed SSTR1 to 5, have been identified and cloned. The precise functional distinction between these receptor subtypes has not yet been fully elucidated.